Pyxis Oncology (PYXS) Research & Development (2020 - 2026)

Pyxis Oncology (PYXS) has reported Research & Development for 7 consecutive years, with $16.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 6.28% year-over-year to $16.1 million in Q2 2026; TTM through Jun 2026 was $72.7 million, a 10.26% increase from a year earlier, with the FY2025 full-year figure at $73.7 million, up 25.45% from the prior year.
• Research & Development was $16.1 million for Q2 2026 at Pyxis Oncology, down from $21.7 million in the prior quarter.
• Over five years, Research & Development peaked at $29.9 million in Q4 2022 and troughed at $11.4 million in Q2 2023.
• A 5-year average of $16.7 million and a median of $17.0 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 435.73% in 2022 and plunged 61.12% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $29.9 million in 2022, then sank by 61.12% to $11.6 million in 2023, then gained by 20.82% to $14.0 million in 2024, then jumped by 54.81% to $21.7 million in 2025, then retreated by 26.04% to $16.1 million in 2026.
• The last three Research & Development figures came in at $16.1 million (Q2 2026), $21.7 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.